Bedard, Philippe L <br/><br/>
A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Feb 2015 
 - 730-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-14-1814  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Aminopyridines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Disease-Free Survival<br/>Dose-Response Relationship, Drug<br/>Female<br/>Humans<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Morpholines--administration & dosage<br/>Neoplasms--drug therapy<br/>Pyridones--administration & dosage<br/>Pyrimidinones--administration & dosage